Replimune Group Inc (NASDAQ: REPL)’s stock price has gone decline by -10.58 in comparison to its previous close of 9.36, however, the company has experienced a -5.10% decrease in its stock price over the last five trading days. zacks.com reported 2024-06-07 that Replimune’s (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.
Is It Worth Investing in Replimune Group Inc (NASDAQ: REPL) Right Now?
REPL has 36-month beta value of 1.25. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for REPL is 45.36M, and currently, short sellers hold a 20.70% ratio of that float. The average trading volume of REPL on July 03, 2024 was 1.22M shares.
REPL’s Market Performance
REPL stock saw an increase of -5.10% in the past week, with a monthly gain of 58.82% and a quarterly increase of 17.39%. The volatility ratio for the week is 8.15%, and the volatility levels for the last 30 days are 11.67% for Replimune Group Inc (REPL). The simple moving average for the past 20 days is 4.16% for REPL’s stock, with a -11.14% simple moving average for the past 200 days.
Analysts’ Opinion of REPL
Many brokerage firms have already submitted their reports for REPL stocks, with Piper Sandler repeating the rating for REPL by listing it as a “Overweight.” The predicted price for REPL in the upcoming period, according to Piper Sandler is $44 based on the research report published on April 17, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see REPL reach a price target of $52. The rating they have provided for REPL stocks is “Overweight” according to the report published on November 19th, 2021.
BTIG Research gave a rating of “Buy” to REPL, setting the target price at $60 in the report published on October 15th of the previous year.
REPL Trading at 20.37% from the 50-Day Moving Average
After a stumble in the market that brought REPL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.53% of loss for the given period.
Volatility was left at 11.67%, however, over the last 30 days, the volatility rate increased by 8.15%, as shares surge +53.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.77% upper at present.
During the last 5 trading sessions, REPL fell by -5.10%, which changed the moving average for the period of 200-days by -54.78% in comparison to the 20-day moving average, which settled at $8.18. In addition, Replimune Group Inc saw -0.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REPL starting from Xynos Konstantinos, who sale 15,881 shares at the price of $7.50 back on Jun 07 ’24. After this action, Xynos Konstantinos now owns 117,131 shares of Replimune Group Inc, valued at $119,108 using the latest closing price.
Astley-Sparke Philip, the Executive Chairman of Replimune Group Inc, sale 37,928 shares at $6.47 during a trade that took place back on May 16 ’24, which means that Astley-Sparke Philip is holding 1,487,350 shares at $245,394 based on the most recent closing price.
Stock Fundamentals for REPL
The total capital return value is set at -0.52. Equity return is now at value -46.42, with -38.05 for asset returns.
Based on Replimune Group Inc (REPL), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.44. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -35.26.
Currently, EBITDA for the company is -234.04 million with net debt to EBITDA at -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.72.
Conclusion
To put it simply, Replimune Group Inc (REPL) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
